ClinicalTrials.gg
CompletedNCT01076075Updated Jun 5, 2017Results posted

A Study to Evaluate the Safety and Efficacy of Sitagliptin 100 mg in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control (MK-0431-229)

A Phase 3 interventional study of Sitagliptin phosphate and Comparator: placebo to pioglitazone in Type 2 Diabetes Mellitus, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years to 78 Years. Per ClinicalTrials.gov, last updated 2017-06-05.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
427
Allocation
Randomized
Ages
18 Years to 78 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 — 3 open to participants now, 5 under way, none of them phase 3. sitagliptin · Diabetes Mellitus, Type 2.

Enrollment
41st of 197
427 · median 102
Started
2010
with 22 others
Phase 3
74 of 198
none open now
Registered
82nd of 198
by date
Lead sponsor
70 of 198
Merck Sharp & Dohme LLC

Among the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, this one is the 41st largest by enrollment of the 197 interventional ones that give a count, is one of 23 that started in 2010, is one of 74 in phase 3, and was the 82nd registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

3 of the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About sitagliptin

sitagliptin: first FDA approval 2006 (JANUVIA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years to 78 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

This study will evaluate whether the addition of Sitagliptin treatment provides a greater decrease in A1C levels compared to placebo in participants with inadequate glycemic control on sulfonylurea and metformin combination therapy.

03

Conditions studied

  • Type 2 Diabetes Mellitus

Keywords

  • Type 2 Diabetes Mellitus
04

Who can participate

Ages eligible
18 Years to 78 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Type 2 diabetes mellitus
  • of ≥7.5% and ≤10.5%
  • Currently taking a stable dose of metformin (at least 1500 mg/day) and either glimepiride (at least 2 mg/day) or gliclazide (at least 50% of maximum registered dose) for at least 10 weeks prior to study start
  • Male, or a female who is highly unlikely to conceive

Exclusion criteria

Exclusion Criteria:

  • Type 1 diabetes mellitus or ketoacidosis
  • Taking a dipeptidyl peptidase-4 (DPP-4) inhibitor (such as sitagliptin) or a glucagon-like peptide-1 (GLP-1) mimetic (such as exenatide or liraglutide) or required insulin therapy within 12 weeks prior to study start
  • On a weight loss program not in the maintenance phase or on a weight loss medication
  • History of liver disease, heart failure, heart disease, stroke, high blood pressure, blood disorders, or cancer
  • positive
  • Pregnant
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
427 participants (actual)

Study arms

  • Active comparator
    placebo/pioglitazone

    Phase A (Weeks 0-24): placebo to Sitagliptin 100 mg; Phase B (Weeks 24-54): placebo to Sitagliptin 100 mg + pioglitazone 30 mg

    Drug: Comparator: placebo to Sitagliptin · Drug: Comparator: pioglitazone · Drug: Glimepiride or gliclazide · Drug: Metformin · Drug: Pioglitazone rescue therapy

  • Experimental
    Sitagliptin

    Phase A (Weeks 0-24): Sitagliptin 100 mg; Phase B (Weeks 24-54): Sitagliptin 100 mg + placebo to pioglitazone

    Drug: Sitagliptin phosphate · Drug: Comparator: placebo to pioglitazone · Drug: Glimepiride or gliclazide · Drug: Metformin · Drug: Pioglitazone rescue therapy

Interventions

  • Phase A (Weeks 0-24): Sitagliptin 100 mg once a day for 24 weeks; Phase B (Weeks 24-54): Sitagliptin 100 mg once a day for 30 weeks

    Also known as: Januvia

  • DrugComparator: placebo to pioglitazone

    Phase B (Weeks 24-54): placebo to pioglitazone 30 mg once a day for 30 weeks

  • DrugComparator: placebo to Sitagliptin

    Phase A (Weeks 0-24): placebo to Sitagliptin 100 mg once a day for 24 weeks; Phase B (Weeks 24-54): placebo to Sitagliptin once a day for 30 weeks

  • Phase B (Weeks 24-54): pioglitazone 30 mg once a day for 30 weeks

    Also known as: Actos;

  • DrugGlimepiride or gliclazide

    Phase A (Weeks 0-24): stable dose, as prescribed by investigator, of glimepiride or gliclazide; Phase B (Weeks 24-54): stable dose, as prescribed by investigator, of glimepiride or gliclazide

  • Phase A (Weeks 0-24): stable dose, as prescribed by investigator, of metformin; Phase B (Weeks 24- 54): stable dose, as prescribed by investigator, of metformin

  • Phase A (Weeks 0-24): participants not meeting specific glycemic goals will receive pioglitazone (open label) at a dose determined by the investigator. These participants will not initiate Phase B (Weeks 24-54) double blind pioglitazone.

    Also known as: Actos

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Hemoglobin A1C (%) at Week 24

    Change from baseline reflects the Week 24 value minus the baseline value. A1C represents the percentage of glycosylated hemoglobin.

    Time frame: Baseline and Week 24

  2. Number of Participants With One or More Adverse Events (AEs) - Week 0 to Week 54

    Time frame: Week 0 to Week 54

  3. Number of Participants Discontinuing Study Drug Due to An Adverse Event

    Time frame: Week 0 to Week 54

Secondary outcomes

  1. Change From Baseline in 2-hour Post-Meal Glucose at Week 24

    Change from baseline reflects the Week 24 value minus the baseline value. Two-hour post-meal glucose was measured following a standard meal.

    Time frame: Baseline and Week 24

  2. Change From Baseline in Fasting Plasma Glucose at Week 24

    Change from baseline reflects the Week 24 value minus the baseline value.

    Time frame: Baseline to Week 24

07

Results

Posted Aug 7, 2012

Participant flow

Participant flow — Overall Study
MilestoneSitagliptinPlacebo/Pioglitazone
Started213214
Completed phase a199189
Completed172167
Not completed4147
Withdrew: Adverse event39
Withdrew: Lack of efficacy54
Withdrew: Lost to follow-up65
Withdrew: Other199
Withdrew: Protocol violation01
Withdrew: Withdrawal by subject819

Outcome measures

PrimaryChange From Baseline in Hemoglobin A1C (%) at Week 24

Change from baseline reflects the Week 24 value minus the baseline value. A1C represents the percentage of glycosylated hemoglobin.

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · Percentage of glycosylated hemoglobin
Change From Baseline in Hemoglobin A1C (%) at Week 24
Percentage of glycosylated hemoglobinSitagliptinPlacebo/Pioglitazone
Change From Baseline in Hemoglobin A1C (%) at Week 24-0.84 ± 0.82-0.16 ± 0.84
Statistical analysis
  • Sitagliptin vs Placebo/Pioglitazone · ANCOVA · p = <0.001 · Difference in least squares means: -0.68 · 95% CI -0.87 to -0.50Based on an ANCOVA model controlling for treatment, stratum (type of sulfonylurea) and baseline value.
SecondaryChange From Baseline in 2-hour Post-Meal Glucose at Week 24

Change from baseline reflects the Week 24 value minus the baseline value. Two-hour post-meal glucose was measured following a standard meal.

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · mg/dL
Change From Baseline in 2-hour Post-Meal Glucose at Week 24
mg/dLSitagliptinPlacebo/Pioglitazone
Change From Baseline in 2-hour Post-Meal Glucose at Week 24-36.8 ± 60.8-3.3 ± 67.8
Statistical analysis
  • Sitagliptin vs Placebo/Pioglitazone · ANCOVA · p = <0.001 · Difference in least squares means: -33.5 · 95% CI -45.3 to -21.7Based on an ANCOVA model controlling for treatment, stratum (type of sulfonylurea) and baseline value.
SecondaryChange From Baseline in Fasting Plasma Glucose at Week 24

Change from baseline reflects the Week 24 value minus the baseline value.

Time frame:
Baseline to Week 24
Reported as:
Least squares mean · mg/dL
Change From Baseline in Fasting Plasma Glucose at Week 24
mg/dLSitagliptinPlacebo/Pioglitazone
Change From Baseline in Fasting Plasma Glucose at Week 24-13.2 (-18.8 to -7.7)5.3 (-0.2 to 10.9)
Statistical analysis
  • Sitagliptin vs Placebo/Pioglitazone · ANCOVA · p = <0.001 · Difference in least squares means: -18.6 · 95% CI -26.4 to -10.7Based on an ANCOVA model controlling for treatment, stratum (type of sulfonylurea) and baseline value.
PrimaryNumber of Participants With One or More Adverse Events (AEs) - Week 0 to Week 54
Time frame:
Week 0 to Week 54
Reported as:
Number · participants
Number of Participants With One or More Adverse Events (AEs) - Week 0 to Week 54
participantsSitagliptinPlacebo/Pioglitazone
Number of Participants With One or More Adverse Events (AEs) - Week 0 to Week 54120122
PrimaryNumber of Participants Discontinuing Study Drug Due to An Adverse Event
Time frame:
Week 0 to Week 54
Reported as:
Number · participants
Number of Participants Discontinuing Study Drug Due to An Adverse Event
participantsSitagliptinPlacebo/Pioglitazone
Number of Participants Discontinuing Study Drug Due to An Adverse Event39

Adverse events

Collected over Week 0 to Week 54. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Sitagliptin—6/210 (2.9%)49/210 (23.3%)
Placebo/Pioglitazone—9/212 (4.2%)44/212 (20.8%)
Most frequent serious events
Showing 10 of 18
Most frequent serious events
EventSitagliptinPlacebo/Pioglitazone
Atrial flutterCardiac disorders1/2100/212
CholelithiasisHepatobiliary disorders1/2100/212
GangreneInfections and infestations1/2100/212
Tooth abscessInfections and infestations1/2100/212
Ischaemic strokeNervous system disorders1/2100/212
Nasal inflammationRespiratory, thoracic and mediastinal disorders1/2100/212
Angina pectorisCardiac disorders0/2101/212
Abscess limbInfections and infestations0/2101/212
AppendicitisInfections and infestations0/2101/212
CellulitisInfections and infestations0/2101/212
Most frequent other events
Most frequent other events
EventSitagliptinPlacebo/Pioglitazone
HypoglcaemiaMetabolism and nutrition disorders38/21031/212
Upper respiratory tract infectionInfections and infestations14/21015/212

Baseline characteristics

Age, Continuous
Age, Continuous(years)SitagliptinPlacebo/PioglitazoneTotal
Mean54.4 ± 9.655.4 ± 10.254.9 ± 9.9
Sex: Female, Male
Sex: Female, Male(Participants)SitagliptinPlacebo/PioglitazoneTotal
Female115114229
Male9598193
Hemoglobin A1C
Hemoglobin A1C(Percentage of glycosylated hemoglobin)SitagliptinPlacebo/PioglitazoneTotal
Mean8.4 ± 0.88.4 ± 0.98.4 ± 0.8
2-Hour Post-Meal Glucose
2-Hour Post-Meal Glucose(mg/dL)SitagliptinPlacebo/PioglitazoneTotal
Mean240.3 ± 60.6243.3 ± 68.8241.8 ± 64.8
Fasting Plasma Glucose
Fasting Plasma Glucose(mg/dL)SitagliptinPlacebo/PioglitazoneTotal
Mean164.8 ± 40.8165.0 ± 43.9164.9 ± 42.4
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Moses RG, Round E, Shentu Y, Golm GT, O'neill EA, Gantz I, Engel SS, Kaufman KD, Goldstein BJ. A randomized clinical trial evaluating the safety and efficacy of sitagliptin added to the combination of sulfonylurea and metformin in patients with type 2 diabetes mellitus and inadequate glycemic control. J Diabetes. 2016 Sep;8(5):701-11. doi: 10.1111/1753-0407.12351. Epub 2016 Feb 3. PubMed 26625270 ↗

Individual participant data

Plan to share: Yes — http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf http://engagezone.msd.com/ds_documentation.php

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2010 to primary completion in Jul 2011, 13 months.

Results were first posted in Aug 2012, 1 year after primary completion.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 13 months is below that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 24, 2010
First posted
Feb 25, 2010
StartActual
Jun 3, 2010
Primary completionActual
Jul 11, 2011
CompletionActual
Jan 19, 2012
Results first posted
Aug 7, 2012
Last update
Jun 5, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 5, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01076075
Responsible party
Sponsor
First posted
Feb 25, 2010
Start date
Jun 3, 2010
Primary completion
Jul 11, 2011
Completion
Jan 19, 2012
Results posted
Aug 7, 2012
Last update
Jun 5, 2017

Study contacts

Medical Monitor
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sitagliptin

Start the discussion